Get the Stockscreener App
9.46
4.76%
0.43
After Hours:
9.42
-0.04
-0.42%
Anavex Life Sciences Corporation stock is traded at $9.46, with a volume of 1.24M.
It is up +4.76% in the last 24 hours and up +65.53% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
See More
Previous Close:
$9.03
Open:
$9.1
24h Volume:
1.24M
Relative Volume:
1.18
Market Cap:
$800.71M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-14.33
EPS:
-0.66
Net Cash Flow:
$-29.31M
1W Performance:
+3.84%
1M Performance:
+65.53%
6M Performance:
+143.19%
1Y Performance:
+33.43%
1-Day Range:
$8.875
$9.80
1-Week Range:
$8.69
$10.35
52-Week Range:
$3.25
$10.45
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.46 | 800.71M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 8.1%Still a Buy? - MarketBeat
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from HC Wainwright - MarketBeat
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA - The Manila Times
Anavex Submits Breakthrough Oral Alzheimer's Drug to European Regulators | AVXL Stock News - StockTitan
Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal - The Manila Times
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 4.1%Time to Sell? - MarketBeat
Nwam LLC Purchases New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by GSA Capital Partners LLP - MarketBeat
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 52-Week HighShould You Buy? - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1%Here's Why - MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
Anavex: Understanding Their Latest Alzheimer's Data News With Caution (NASDAQ:AVXL) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan
Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat
Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex
Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade) (NASDAQ:AVXL) - Seeking Alpha
The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News
Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News
Anavex Life Sciences Corporation (AVXL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Anavex Life Sciences Corporation [AVXL] Director makes an insider acquire of 2,835 shares worth 10,319. - Knox Daily
Australian Vanadium gets interest for $31 million finance support - Mining.com.au
AVXL Shares Experience Surge in Value - Knox Daily
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near? - Yahoo Finance
Australian Vanadium receives Letter of Interest for US$31 million in debt financing from EXIM - Proactive Investors UK
Ratios Revealed: Decoding Anavex Life Sciences Corporation (AVXL)’s Financial Health - The Dwinnex
Oops! Disney May Have Just Spoiled their Next Marvel Series - Bleeding Fool
A better buy-in window may exist right now for Anavex Life Sciences Corporation (AVXL) - SETE News
Alzheimer's Drugs Market Report Details Size, Share, Demand, Forecast, Trends To 2033 - WhaTech
AVXL’s Market Balancing Act: Weighing Gains and Losses in 2023 - The InvestChronicle
Investing in Anavex Life Sciences Corporation (AVXL) might be a great opportunity, but the stock is a bit overvalued - US Post News
Anavex Life Sciences Corporation (AVXL) receives a Neutral rating from Cantor Fitzgerald - Knox Daily
Market Recap: Anavex Life Sciences Corporation (AVXL)’s Positive Momentum, Closing at 5.21 - The Dwinnex
AVXL Stock Sees Decline of Approximately -8.72% in Last Five Days - Knox Daily
Investors in cash trouble should check out Anavex Life Sciences Corporation (AVXL) - SETE News
Ratios Reveal: Breaking Down Anavex Life Sciences Corporation (AVXL)’s Financial Health - The Dwinnex
Investing in Anavex Life Sciences Corporation (AVXL): What You Must Know - Knox Daily
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
A History of Outperforming Analyst Forecasts and Beating the Odds: Anavex Life Sciences Corporation (AVXL) - SETE News
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):